GLP-1 Cost Without Insurance: Every Cash-Pay Route Compared
Released · Last reviewed
Without insurance, compounded semaglutide ($119-299) is usually cheapest, followed by oral Wegovy (from $149 for qualifying patients), brand self-pay via NovoCare/LillyDirect (~$299-349), and brand list (~$1,086-1,349).
- Uninsured, compounded GLP-1s are usually the cheapest legitimate route.
- Oral Wegovy from ~$149/mo (qualifying patients, specified doses) is a competitive approved option.
- Brand self-pay (NovoCare ~$349, LillyDirect ~$299) buys the approved product.
- Model effective monthly cost after all fees, and confirm renewal pricing.
The cash-pay landscape
Without insurance, GLP-1 pricing spans an enormous range — from about $145 per month for compounded semaglutide to about $1,349 list for brand Wegovy. The route you choose depends on whether you prioritize the lowest price or an FDA-approved product.
Cash pricing does not vary by state; it is set by the provider or manufacturer nationally. So the decision is about product type, not geography.
Compounded: usually cheapest
Compounded semaglutide from about $145 per month and compounded tirzepatide from about $199 are the lowest-cost legitimate routes for most uninsured patients. The trade-off is that these are not FDA-approved and carry no formulation-specific trial evidence.
Verify the dispensing pharmacy is named and state-licensed before enrolling, and confirm there is no hidden membership that inflates the effective cost.
| Route | Monthly | FDA-approved? |
|---|---|---|
| Compounded semaglutide | $145–299 | No |
| Oral Wegovy (qualifying) | from $149 | Yes |
| Compounded tirzepatide | $199–297 | No |
| Brand self-pay | $299–349 | Yes |
| Brand list | $1,086–1,349 | Yes |
Brand self-pay options
For patients who want the approved product without insurance, manufacturer self-pay programs are the route. NovoCare offers Wegovy near $349 per month; LillyDirect offers Zepbound vials from about $299. The oral Wegovy tablet is available from about $149 per month for qualifying patients at specified doses, though promotional pricing can change and some offers have expiration dates.
These cost more than compounded but deliver FDA-approved medication with full trial backing.
| Route | Trade-off |
|---|---|
| Compounded | Cheapest, not FDA-approved |
| Oral Wegovy | Approved pill, dose-limited pricing |
| Brand self-pay | Approved, higher cost |
Ranked by cost
For a cash-pay patient, the rough ranking is: compounded semaglutide (lowest), oral Wegovy for qualifying patients, compounded tirzepatide, brand self-pay via LillyDirect or NovoCare, and brand list (highest, and rarely what anyone should pay). Your clinician determines which is appropriate for you.
The cheapest option is not automatically best: weigh pharmacy transparency, dose coverage, and whether you need an approved product against the price difference.
Frequently asked questions
What is the cheapest GLP-1 without insurance?
Compounded semaglutide from about $145/month is usually the cheapest legitimate route, though it is not FDA-approved.
Is there an approved option under $200?
The oral Wegovy tablet is available from about $149/month for qualifying patients at specified doses, though offers can change and expire.
Does cash price vary by state?
No. GLP-1 cash pricing is set nationally by the provider or manufacturer; it does not change by state.
Sources
- FDA — human drug compounding and GLP-1 status.
- NovoCare and LillyDirect pricing, captured September 2026.
- Evidence ledger: evidence-ledger.csv.
The numbers behind this page
Checking the figures in this entry
Every price quoted in this entry comes from the programme's own pricing page and carries the date it was captured. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
21 programmes print a price for both molecules on their own pages. Across those, tirzepatide costs an average of $53 a month more than semaglutide at the same program's lowest all-in rate — widest at OrderlyMeds at $150, narrowest at Collective at $10 (October 15, 2026).
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
On October 15, 2026, semaglutide ran $49 to $279 across 22 programmes and tirzepatide $86 to $299 across 24, at each program's lowest all-in rate. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied.
Questions this page answers
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.